Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05157945 · ClinicalTrials.gov registry record · Phase 2
ALTO-300 in Depression (ALTO-300-004)
A Phase 2 study of Major Depressive Disorder, sponsored by Alto Neuroscience.
- Completed
- Registry status
- Phase 2
- Development phase
- 148
- Enrollment target
- 4
- Study locations
NCT05157945 is a Phase 2 study of Major Depressive Disorder that has completed, run by Alto Neuroscience. The registered enrollment target is 148 participants, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (61% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT05157945, a Phase 2 study of Major Depressive Disorder, has completed, sponsored by Alto Neuroscience.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 148 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to collect biologically-based data for defining predictors and correlates of the effects of ALTO-300.
Conditions Studied
Interventions
- DRUG ALTO-300 PO Tablet
Study Locations (4)
Georgia
- Cerebral - Atlanta - Atlanta
Mississippi
- Site 171 - Jackson
New York
- Cerebral - New York City - New York
Texas
- Cerebral - Dallas - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 148 participants |
| Start Date | 2022-02-03 |
| Est. Completion | 2023-05-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05157945
The ClinicalTrials.gov registry entry for NCT05157945 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 148 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (61% lower). The listed sponsor is Alto Neuroscience, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Major Depressive Disorder appearing as the primary indexed condition, and to 1 intervention - of which ALTO-300 PO Tablet is the first listed.
NCT05157945 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Georgia, Mississippi, New York.
Frequently Asked Questions
What is clinical trial NCT05157945 about?
NCT05157945 is a clinical study titled "ALTO-300 in Depression (ALTO-300-004)". The purpose of this study is to collect biologically-based data for defining predictors and correlates of the effects of ALTO-300.
What is the current status of trial NCT05157945?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 148 participants. The study started on 2022-02-03. Estimated completion is 2023-05-05.
What conditions does trial NCT05157945 study?
This clinical trial studies the following conditions: Major Depressive Disorder.
What interventions are being tested in trial NCT05157945?
The interventions under investigation include: ALTO-300 PO Tablet (DRUG).
Who is sponsoring clinical trial NCT05157945?
This trial is sponsored by Alto Neuroscience, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05157945 being conducted?
This trial has 4 study locations across Georgia, Mississippi, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
RECRUITING · Phase 2
-
A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
RECRUITING · Phase 2
-
Study of ALTO-300 in MDD
RECRUITING · Phase 2
-
Regulation of Affect and Physiology in Depression
RECRUITING · Phase 2
-
Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2) in Major Depressive Disorder (MDD)
RECRUITING · Phase 2
-
A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.